

Section 1 - Cancer systems biology: An overview

- 1: The necessary existence of cancer and its progression from first principles of cell state dynamics, *Sui Huang*
- 2: Non-genetic intratumoral heterogeneity and phenotypic plasticity as consequences of microenvironment-driven epigenomic dysregulation, *Vera Pancaldi and Jean- Pascal Capp*
- 3: Dimensions of cellular plasticity: Epithelial– mesenchymal transition, cancer stem cells, and collective cell migration, *Caterina A.M. La Porta and Stefano Zapperi*
- 4: Phenotypic switching in cancer: A systems- level perspective, *Divyjoy Singh, Abhay Gupta, Mohit Kumar Jolly, and Prakash Kulkarni*
- 5: Morphological state transition during epithelial– mesenchymal transition, *Biplab Bose*

Section 2 - Cancer systems biology: New paradigms

- 6: Evolution- informed multilayer networks: Overlaying comparative evolutionary genomics with systems- level analyses for cancer drug discovery, *Laurie Graves, Ayalur Raghu Subbalakshmi, William C. Eward, Mohit Kumar Jolly, and Jason A. Somarelli*
- 7: Landscape of cell- fate decisions in cancer cell plasticity, *Jintong Lang, Chunhe Li, and Jinzhi Lei*
- 8: The road to cancer and back: A thermodynamic point of view, *Arnab Barua and Haralampos Hatzikirou*
- 9: Cellular plasticity as emerging target against dynamic complexity in cancer, *Paromita Mitra, Uday Saha, Subhashis Ghosh, and Sandeep Singh*
- 10: Modeling phenotypic heterogeneity and cell- state transitions during cancer progression, *Vishaka Gopalan, Sidhartha Goyal, and Sumaiyah Rehman*

Section 3 - Single cell 'omics' analysis

- 11: Decoding drug resistance at a single- cell level using systems- level approaches, *Benedict Anchang and Loukia G. Karacosta*
- 12: Computational methods to infer lineage decision- making in cancer using single-cell data, *Manu Setty*
- 13: Analyzing cancer cell- state transition dynamics through live- cell imaging and high- dimensional single-cell trajectory analyses, *Jianhua Xing and Weikang Wang*
- 14: Emerging single- cell technologies and concepts to trace cancer progression and drug resistance, *Syeda Subia Ahmed, Danielle Pi, Nicholas Bodkin, Vito W. Rebecca, and Yogesh Goyal*

Section 4 - Computational approaches to drug development

- 15: Navigating protein dynamics: Bridging the gap with deep learning and machine intelligence, *Supriyo Bhattacharya*
- 16: Cancer- related intrinsically disordered proteins: Functional insights from energy landscape analysis, *Vitor B.P. Leite, Murilo N. Sanches, and Rafael G. Viegas*
- 17: Targeting RAS, *Priyanka Prakash*

Section 5 - Statistical methods and data mining, machine learning, artificial intelligence, and cloud computing

- 18: The power of connection—enabling collaborative, multimodal data analysis at petabyte scale to advance understanding of oncology, *Brandi N. Davis- Dusenbery, Cera R. Fisher, Rowan Beck, and Zelia F.*

Worman

19: Interpretation of machine learning models in cancer: The role of model-agnostic explainable artificial intelligence, *Colton Ladbury and Arya Amini*

20: Applying cloud computing and informatics in cancer, *Jay G. Ronquillo*

21: Single-cell sequencing analysis focused on cancer immunotherapy, *Luciane T. Kagohara and Joseph Tandurella*

22: Application of artificial intelligence to overcome clinical information overload in cancer, *Arnulf Stenzl, Jenny Ghith, and Bob J.A. Schijvenaars*

23: Application of artificial intelligence in cancer genomics, *Xiwei Wu and Supriyo Bhattacharya*

Section 6 - Biomechanics

24: A role for mechanical heterogeneity in the tumor microenvironment in driving cancer cell invasion, *Madhurima Sarkar, Asadullah, and Shamik Sen*

25: Adaptation of cancer cells to altered stiffness of the extra-cellular matrix, *Christina R. Dollahon, Ting-Ching Wang, Srinikhil S. Vemuri, Suchitaa Sawhney, and Tanmay P. Lele*

26: Decoding mechano-oncology principles through microfluidic devices and biomaterial platforms, *Ajay Tijore, Alka Kumari, and Abhishek Goswami*

27: Understanding contribution of fibroblasts in inception of cancer metastasis from an evolutionary perspective, *Yasir Suhail, Wenqiang Du, Günter Wagner, and Kshitiz*

28: Cell competition in tumorigenesis and epithelial defense against cancer, *Medhavi Vishwakarma and Amrapali Datta*

Section 7 - Translational mathematical oncology

29: Modelling cell population dynamics during chimeric antigen receptor T-cell therapy, *Philipp M. Altrock, Guranda Chitadze, Arne Traulsen, and Frederick L. Locke*

30: Modeling small cell lung cancer biology through deterministic and stochastic mathematical models, *Srisairam Achuthan, Rishov Chatterjee, and Atish Mohanty*

31: Mathematical models of resistance evolution under continuous and pulsed anti-cancer therapies, *Jasmine Foo and Einar Bjarki Gunnarsson*

32: Integrating in silico models with ex vivo data for designing better combinatorial therapies in cancer, *Mohammad Kohandel, Cameron Meaney, and Dorsa Mohammadrezaei*

33: Tumour-immune co-evolution dynamics and its impact on immunotherapy optimization, *Annice Najafi and Jason George*

34: Mechanistic modelling and machine learning to establish structure–activity relationship of nanomaterials for improved tumour delivery, *Maria Jose Peláez, Shreya Goel, Vittorio Cristini, Zhihui Wang, and Prashant Dogra*

Section 8 - Ecology, evolution, and cancer

35: Decoding cancer evolution through adaptive fitness landscapes, *Rowan Barker-Clarke, Eshan S. King, Jeff Maltas, J. Arvid Ågren, Dagim Tadele, and Jacob G. Scott*

36: A case against causal reductionism in acquired therapy resistance, *Andriy Marusyk*

37: Group behaviour and drug resistance in cancer, *Ravi Salgia, Supriyo Bhattacharya, Atish Mohanty, and Govindan Rangarajan*

38: The Fundamentals of evolutionary therapy in cancer, *Jeffrey West, Jill Gallaher, Maximilian A.R. Strobl, Mark Robertson-Tessi, and Alexander R.A. Anderson*

Section 9 - Critical transitions and chaos in cancer

39: Methods for identifying critical transitions during cancer progression, *Smita Deb, Subhendu Bhandary, Mohit Kumar Jolly, and Partha Sharathi Dutta*

40: Chaos and complexity: Hallmarks of cancer progression, *Abicumaran Uthamacumaran*

41: Cancer formation as creation and penetration of unknown life spaces, *Andrzej Kasperski and Henry H. Heng*